Evidence map›Paper›PMID 25490553›Full record

ArticlePloS one2014

Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques.

Emma J Bowles, Torben Schiffner, Maximillian Rosario, Gemma A Needham, Meghna Ramaswamy, Joanna McGouran, Benedikt Kessler, Celia LaBranche, Andrew J McMichael, David Montefiori and 3 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Emma J BowlesMRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe Hospital, Oxford, United Kingdom.
Torben SchiffnerSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Maximillian RosarioMRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe Hospital, Oxford, United Kingdom.
Gemma A NeedhamSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Meghna RamaswamyDivision of Retrovirology, Centre for AIDS Reagents, National Institute of Biological Standards and Control, South Mimms, Potters Bar, Herts, United Kingdom.
Joanna McGouranHenry Wellcome Building for Molecular Physiology, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Benedikt KesslerHenry Wellcome Building for Molecular Physiology, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Celia LaBrancheDivision of Surgical Sciences, Duke University Medical Center, Durham, North Carolina, United States of America.
Andrew J McMichaelMRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe Hospital, Oxford, United Kingdom.
David MontefioriDivision of Surgical Sciences, Duke University Medical Center, Durham, North Carolina, United States of America.
Quentin J SattentauSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Tomáš HankeMRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe Hospital, Oxford, United Kingdom; The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford, United Kingdom.
Guillaume B E Stewart-JonesMRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe Hospital, Oxford, United Kingdom.
University of Oxford · GBJohn Radcliffe Hospital · GBDuke Medical Center · USMRC Human Immunology Unit · GBNational Institute for Biological Standards and Control · GB

Funding

Medical Research Council G0000635Medical Research Council G1001757Medical Research Council MR/K012037/1
6 · The paper itself

Abstract

Eliciting neutralizing antibodies capable of inactivating a broad spectrum of HIV-1 strains is a major goal of HIV-1 vaccine design. The challenge is that envelopes (Envs) of circulating viruses are almost certainly different from any Env used in a vaccine. A novel immunogen composed of a highly diverse set of gp140 Envs including subtypes A, B, C, D and F was developed to stimulate a more cross-neutralizing antibody response. Env heterotrimers composed of up to 54 different gp140s were produced with the aim of focusing the response to the conserved regions of Env while reducing the dominance of any individual hypervariable region. Heterotrimeric gp140 Envs of inter- and intra-subtype combinations were shown to bind CD4 and a panel of neutralizing monoclonal antibodies with similar affinity to monovalent UG37 gp140. Macaques immunized with six groups of heterotrimer mixtures showed slightly more potent neutralizing antibody responses in TZM-BL tier 1 and A3R5 tier 2 pseudovirus assays than macaques immunized with monovalent Env gp140, and exhibited a marginally greater focus on the CD4-binding site. Carbopol enhanced neutralization when used as an adjuvant instead of RIBI in combination with UG37 gp140. These data indicate that cross-subtype heterotrimeric gp140 Envs may elicit some improvement of the neutralizing antibody response in macaques compared to monovalent gp140 Env.

Indexed as

AIDS VaccinesAntibody FormationAnimalsAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV-1Macaca mulattaNeutralization TestsAIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency Virusgp140 envelope protein, Human immunodeficiency virus 1

Identifiers

PMID25490553
PMCPMC4260879
OpenAlexW2090485380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.